ETF Holdings Breakdown of MDGL

Stock NameMadrigal Pharmaceuticals Inc
TickerMDGL(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS5588681057
LEI549300CHIMT2EUSNJB60

News associated with MDGL

Canaccord Genuity Group Forecasts Strong Price Appreciation for Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock
Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) had its price target raised by Canaccord Genuity Group from $394.00 to $420.00 in a research report released on Friday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. Several other research firms have also recently weighed in on MDGL. Citigroup increased their price target on […] - 2025-05-05 09:18:49
UBS Group Increases Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target to $458.00
Madrigal Pharmaceuticals (NASDAQ:MDGL – Free Report) had its target price boosted by UBS Group from $441.00 to $458.00 in a research report sent to investors on Friday morning,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. Several other research firms have also recently issued reports on MDGL. Citigroup increased their […] - 2025-05-05 07:24:53
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Sold by Mariner LLC
Mariner LLC lowered its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 41.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,746 shares of the biopharmaceutical company’s stock after selling 1,252 shares during the quarter. Mariner LLC’s […] - 2025-05-02 08:08:50
CANADA LIFE ASSURANCE Co Increases Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
CANADA LIFE ASSURANCE Co increased its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 81.1% during the fourth quarter, Holdings Channel.com reports. The firm owned 2,334 shares of the biopharmaceutical company’s stock after buying an additional 1,045 shares during the period. CANADA LIFE ASSURANCE Co’s holdings in Madrigal Pharmaceuticals were worth […] - 2025-04-30 08:44:14
1,467 Shares in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Purchased by Cerity Partners LLC
Cerity Partners LLC acquired a new position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 1,467 shares of the biopharmaceutical company’s stock, valued at approximately $453,000. Several other large investors have […] - 2025-04-23 08:38:50
Envestnet Asset Management Inc. Buys 334 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Envestnet Asset Management Inc. grew its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 2.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 15,001 shares of the biopharmaceutical company’s stock after buying an additional 334 shares during […] - 2025-04-23 07:20:54
Legal & General Group Plc Sells 312 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Legal & General Group Plc cut its stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 2.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 14,463 shares of the biopharmaceutical company’s stock after selling 312 shares during the quarter. Legal & General […] - 2025-04-22 08:45:20
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Bought by Barclays PLC
Barclays PLC grew its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 32.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 53,253 shares of the biopharmaceutical company’s stock after buying an additional 12,974 shares during the […] - 2025-04-21 09:00:46
Wells Fargo & Company MN Increases Stock Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Wells Fargo & Company MN grew its position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 19.1% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 34,923 shares of the biopharmaceutical company’s stock after acquiring an additional 5,604 shares during the period. Wells Fargo & Company MN’s holdings in Madrigal Pharmaceuticals were worth […] - 2025-04-17 08:44:53
LPL Financial LLC Has $1.61 Million Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
LPL Financial LLC lifted its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 10.1% during the fourth quarter, Holdings Channel.com reports. The firm owned 5,220 shares of the biopharmaceutical company’s stock after buying an additional 480 shares during the period. LPL Financial LLC’s holdings in Madrigal Pharmaceuticals were worth $1,611,000 at […] - 2025-04-17 08:44:49
Orion Portfolio Solutions LLC Lowers Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Orion Portfolio Solutions LLC lowered its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 2.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,094 shares of the biopharmaceutical company’s stock after selling 90 shares during the period. […] - 2025-04-06 09:25:05
Corebridge Financial Inc. Sells 442 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Corebridge Financial Inc. reduced its holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 4.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,938 shares of the biopharmaceutical company’s stock after selling 442 shares during the quarter. Corebridge Financial Inc.’s holdings in […] - 2025-04-01 09:36:53
Vanguard Group Inc. Sells 127,633 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Vanguard Group Inc. lowered its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 7.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,706,135 shares of the biopharmaceutical company’s stock after selling 127,633 shares during […] - 2025-04-01 09:02:50
KLP Kapitalforvaltning AS Invests $802,000 in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
KLP Kapitalforvaltning AS purchased a new stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 2,600 shares of the biopharmaceutical company’s stock, valued at approximately $802,000. Other large investors have also recently bought and sold […] - 2025-04-01 08:16:59
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives $378.44 Average PT from Brokerages
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the ten research firms that are presently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, seven have assigned a buy recommendation […] - 2025-03-26 05:52:55
Raymond James Financial Inc. Makes New $16.62 Million Investment in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Raymond James Financial Inc. bought a new position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 53,846 shares of the biopharmaceutical company’s stock, valued at approximately $16,615,000. Several other hedge funds also recently bought and sold […] - 2025-03-18 07:54:56
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Bought by Victory Capital Management Inc.
Victory Capital Management Inc. lifted its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 2,981.8% in the fourth quarter, Holdings Channel reports. The firm owned 70,635 shares of the biopharmaceutical company’s stock after buying an additional 68,343 shares during the period. Victory Capital Management Inc.’s holdings in Madrigal Pharmaceuticals were worth […] - 2025-03-12 07:52:53
Oppenheimer Asset Management Inc. Decreases Stock Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Oppenheimer Asset Management Inc. decreased its position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 24.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,132 shares of the biopharmaceutical company’s stock after selling 375 shares during the quarter. Oppenheimer Asset Management Inc.’s holdings […] - 2025-03-07 10:56:53
Principal Financial Group Inc. Sells 96 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Principal Financial Group Inc. cut its holdings in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 5.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,530 shares of the biopharmaceutical company’s stock after selling 96 shares during […] - 2025-03-07 09:22:51
Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 6.8% on Insider Selling
Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) were down 6.8% during trading on Monday after an insider sold shares in the company. The company traded as low as $322.44 and last traded at $317.97. Approximately 109,233 shares traded hands during trading, a decline of 74% from the average daily volume of 422,250 […] - 2025-03-04 06:37:13
Madrigal Pharmaceuticals (NASDAQ:MDGL) Hits New 1-Year High on Better-Than-Expected Earnings
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) reached a new 52-week high on Thursday after the company announced better than expected quarterly earnings. The stock traded as high as $377.46 and last traded at $355.88, with a volume of 1187957 shares traded. The stock had previously closed at $309.49. The biopharmaceutical company reported ($2.71) […] - 2025-02-28 09:30:56
State of New Jersey Common Pension Fund D Reduces Stock Position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
State of New Jersey Common Pension Fund D lessened its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Free Report) by 13.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 6,682 shares of the biopharmaceutical company’s stock after selling […] - 2025-02-23 09:44:57
Head-To-Head Survey: Madrigal Pharmaceuticals (NASDAQ:MDGL) & Ovid Therapeutics (NASDAQ:OVID)
Madrigal Pharmaceuticals (NASDAQ:MDGL – Get Free Report) and Ovid Therapeutics (NASDAQ:OVID – Get Free Report) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, analyst recommendations, earnings and institutional ownership. Analyst Ratings This is a summary of recent […] - 2025-02-19 06:33:53
Brokerages Set Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Target Price at $351.67
Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the thirteen analysts that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and ten have issued a buy recommendation […] - 2025-02-04 07:03:10

MDGL institutional holdings

The following institutional investment holdings of MDGL have been identified

Date ETF ISIN/Name Num Shares Book value
2025-05-08 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 9,119USD 2,731,779
2025-05-08 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 1,495USD 447,857 0.2%
2025-05-08 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 10,507USD 3,147,582
2025-05-08 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 10,507USD 3,147,582 0.2%
2025-05-08 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 34USD 10,185 0.2%
Total =31,662 USD 9,484,985
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.